Development of anti-Abeta vaccination as a promising therapy for Alzheimer's disease.
Alzheimer's disease is the most common cause of dementia characterized by progressive neurodegeneration. Recently, a vaccine therapy for Alzheimer's disease was developed as a curative treatment. Although clinical trials of active vaccination for Alzheimer's disease were halted due to the development of meningoencephalitis in some patients, the clinical and pathological findings of treated patients suggest that the vaccine therapy is effective. Hence, newly designed vaccines are being invented to control excessive T-cell immune reactions after the human clinical trial. In this article, we will review conventional vaccine therapies and newly developed vaccine therapies, mainly DNA vaccines, for possible clinical application in the near future.
Okura
Yoshio
Y
Department of Molecular Neuropathology, Tokyo Metropolitan Institute for Neuroscience, Tokyo, Japan.
Matsumoto
Yoh
Y
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000276:immunology; D023582:Alzheimer Vaccines / Q000276:immunology / Q000494:pharmacology*; D016229:Amyloid beta-Peptides / Q000276:immunology / Q000494:pharmacology*; D000818:Animals; D018849:Controlled Clinical Trials as Topic; D015195:Drug Design; D006801:Humans; D051379:Mice; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D014611:Vaccination; D019444:Vaccines, DNA / Q000276:immunology / Q000627:therapeutic use
C437846:AN-1792; D023582:Alzheimer Vaccines; D016229:Amyloid beta-Peptides; D019444:Vaccines, DNA